Adial Pharmaceuticals Inc (ADIL) Stock AnalysisADILStock AnalysisAdial Pharmaceuticals Inc

Adial Pharmaceuticals, Inc. is a biopharmaceutical company. Its lead program is AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis. AT177 is a fully synthetic, patented, oral AhR agonist designed to restore mucosal immune homeostasis at the site of disease with minimal systemic exposure. AT177's active ingredient is a prodrug of indirubin, a potent AhR agonist within indigo naturalis, a botanical extract with clinical efficacy in ulcerative colitis. AT177's colon-targeted formulation delivers therapeutic AhR engagement directly to the colonic mucosa with exquisite gut restriction, minimizing the systemic AhR exposure associated with adverse effects. Its historical investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder in heavy drinking patients. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Adial Pharmaceuticals is a good buy right now due to its recent acquisition of Azora Therapeutics, which has the potential to significantly enhance its product pipeline. The stock is currently priced at $5.60, and analysts have set a price target of $11, indicating a potential upside of 96.4%. Additionally, the RSI of 55.352 suggests that the stock is neither overbought nor oversold, providing a favorable entry point for long-term investors. The main risk is the company's negative earnings, with a net income of -2,022,392 USD in Q1 2026, which could impact future performance if not addressed.

2 analysts cover ADIL: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 1.50.